Sobi will showcase extensive research and clinical outcomes at ISTH 2025

STOCKHOLM, June 20, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will be presenting a wide range of clinical study updates at the annual International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington (21-25 June). With ten (10) presentations, Sobi's clinical teams will showcase new data for avatrombopag to treat children with ITP, surgery outcomes using efanesoctocog alfa, and abstracts on specific long-term haemophilia studies.
"Attending ISTH is an important part of our commitment to collaboration and knowledge sharing so we can further advance treatments for those living with haemophilia, immune thrombocytopenia, and other rare blood conditions", said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi.
"We are proud to be showcasing abstracts as part of the ISTH programme, including Doptelet abstracts that present new data related to children living with ITP, Altuvoct outcomes for perioperative management, and joint health outcomes from a long-term extension study, as well as final outcomes from the B-MORE study. Many people living with rare conditions have unmet needs, and we are proud to present additional data advancing treatments for these rare conditions."
Data to be presented at ISTH 2025
ALTUVOCT® (efanesoctocog alfa)
OC 64.4: Major Surgical Outcomes with Efanesoctocog Alfa: 4 Years' Experience in the XTEND Clinical Program
Presenting author: Liane Khoo
Oral presentation
Session date: Tuesday 24 June
Session time: 14:45 - 16:00 EDT
Location: 151 A&B, Walter E. Washington CC Convention Center
OC 20.5: Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children: XTEND-ed Second Interim Analysis
Presenting author: Lynn Malec
Oral presentation
Session date: Sunday 22 June
Session time: 14:45 - 16:00 EDT
Location: Ballroom A-C, Walter E. Washington CC Convention Center
PB0847: Minor Surgeries Outcomes with Efanesoctocog Alfa: 4 Years' Experience in the XTEND Clinical Program
Presenting author: Pratima Chowdary
Poster presentation
Session date: Monday 23 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
PB1425: Joint Health Outcomes with Efanesoctocog Alfa in Adults/Adolescents from XTEND-1 Continuing XTEND-ed
Presenting author: Christoph Königs
Poster presentation
Session date: Tuesday 24 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
General Haemophilia
PB0778: Addressing unmet medical needs and health inequities in haemophilia A: expertconsensus statements
Presenting author: Cédric Hermans
Poster presentation
Session date: Monday 23 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
PB0816: Extravascular distribution of factor IX: evidence and relevance for haemophilia B replacement therapy
Presenting author: Cédric Hermans
Poster presentation
Session date: Monday 23 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
PB1439: Monitoring Joint Health in Haemophilia Patients in Spain: Updated Analysis of the JOIN-US Project
Presenting author: María Teresa Álvarez Román
Poster presentation
Session date: Tuesday 24 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
ALPROLIX® (rFIXFc)
PB0868: Real-World Effectiveness and Usage
of Recombinant Factor IX Fc: Final Data from the B-MORE Study
Presenting author: Heidi Glosli
Poster presentation
Session date: Monday 23 June
Session time: 13:45 – 14:45 EDT
Location: Exhibition Hall
Doptelet® (avatrombopag)
PB0348: Consistent Response to Avatrombopag for the Treatment of Children with ITP Across Various Baseline Characteristics
Presenting author: Rachael F. Grace
Poster presentation
Session date: Sunday 22 June
Session time: 13:45 - 14:45 EDT
Location: Exhibition hall
PB0364: Evaluation of Efficacy and Safety of Avatrombopag in Children with ITP Based on Disease Duration
Presenting author: Rachael F. Grace
Poster presentation
Session date: Sunday 22 June
Session time: 13:45 - 14:45 EDT
Location: Exhibition hall
OC 65.3: Real-World Outcomes of Avatrombopag Treatment in Primary ITP Stratified by Prior TPO-RA Exposure
Presenting author: Srikanth Nagalla
Oral presentation
Session date: Tuesday 24 June 2025
Session time: 14:45 – 16:00 EDT
(Presentation time currently in programme: 15:15 – 15:30 EDT)
All abstracts are accessible through the official ISTH website. However, any late-breaking abstracts will only be made available later.
About ALTUVOCT® (efanesoctocog alfa)
ALTUVOCT® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A. ALTUVOCT can be used for all age groups and any disease severity.
About Elocta®/Eloctate® (efmoroctocog alfa)
Elocta®/Eloctate® (efmoroctocog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia A. Elocta/Eloctate can be used for all age groups.
About Alprolix® (eftrenonacog alfa)
Alprolix® (eftrenonacog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia B. Alprolix can be used for all age groups.
About Doptelet® (avatrombopag)
Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure.
About Sobi
Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. Sanofi apply deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Sanofi's team is guided by one purpose: to chase the miracles of science to improve people's lives; this inspires Sanofi to drive progress and deliver positive impact for Sanofi's people and the communities Sanofi serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
About the Sanofi and Sobi collaboration
Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or ALTUVIIIO® in the US, Japan, and Taiwan, and Altuvoct in Europe. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory.
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-will-showcase-extensive-research-and-clinical-outcomes-at-isth-2025,c4166601
The following files are available for download:
https://mb.cision.com/Main/14266/4166601/3514826.pdf
Sobi will showcase extensive research and clinical outcomes at ISTH 2025
View original content:https://www.prnewswire.co.uk/news-releases/sobi-will-showcase-extensive-research-and-clinical-outcomes-at-isth-2025-302486857.html

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Health Line

12 minutes ago

• Health Line

GLP-1 Weight Loss Results Not as Effective in Everyday Life, Study Finds

Researchers report that people taking GLP-1 drugs in daily life don't lose as much weight as those in clinical trials who take the same medications. The researchers add that people using weight loss drugs don't regain weight as quickly as those in clinical trials. One possible reason for the weight loss differential is that people in the 'real world' tend to stop taking these medications sooner than people in clinical trials. People who use commonly prescribed weight loss medications don't lose as much weight as participants in clinical trials, but they also don't regain weight as quickly. That's the conclusion of a new study published on June 10 in the journal Obesity. The study authors reported that the weight loss differential was mainly due to the fact that people tend to stop using GLP-1 drugs sooner than clinical trial participants. They also tend to use lower doses of these medications. The researchers also reported that A1C blood level reductions were similar for both groups of people. The researchers noted that they will initiate further research into what other measures, such as lifestyle changes or bariatric surgery, people may have adopted after discontinuing weight loss medications such as Wegovy and Zepbound. The researchers also want to look into why people stopped using weight loss drugs before their program regimen ended. 'Our findings indicate that treatment discontinuation and use of lower maintenance dosages might reduce the likelihood of achieving clinically meaningful weight reduction in patients who initiate obesity pharmacotherapy with semaglutide or tirzepatide,' the study authors wrote. 'Our findings could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight loss,' they added. 'Real world' use of weight loss medications For their study, researchers looked at the health records of 7,881 adults with obesity or weight management issues who did not have type 2 diabetes. Those people were seen between 2021 and 2023 at the Cleveland Clinic's facilities in Ohio and Florida. Their average age was about 51 years. Nearly 80% of the subjects were white. Of those participants, 6,109 were prescribed a weight loss medication such as Wegovy with the active ingredient semaglutide. The other 1,772 were prescribed a weight loss drug, such as Zepbound, with the active ingredient tirzepatide. About 80% of those subjects were given low doses of their weekly injectable weight loss medications. Researchers reported significant differences between people using weight loss medications in phase 3 clinical trials and those taking the drugs in the 'real world.' For starters, about half of those taking either medication in daily life stopped within the first 12 months. About 51% of those using a tirzepatide drug discontinued its use in that same time period. That compares with only 17% of semaglutide users and between 14% and 16% of tirzepatide users in clinical trials who quit during the first year. In addition, the average weight reduction for semaglutide participants in daily life was nearly 8% after one year while it was 12% for people taking tirzepatide. By comparison, the average weight loss in clinical trials was nearly 15% for semaglutide subjects as well as 15% for people on low dose tirzepatide and 20% for those on a higher dose of that medication. In general, weight loss was greater in people who took weight loss medications for a longer period of time. In addition, about 54% of people who had prediabetes at the start of their treatment plan improved to healthier A1C levels after one year. Around 3% of those studied progressed to type 2 diabetes after 12 months. Weight loss is a long-term commitment Mir Ali, MD, a surgeon and bariatric surgeon as well as the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in California, said the main takeaway from this study is that weight loss is a long-term commitment. Ali wasn't involved in the new study. 'The long-term use of medications is more effective than short-term use,' Ali told Healthline. 'The study confirms that obesity is a chronic condition like diabetes or hypertension.' Sarah Kim, MD, a professor of medicine at the University of California San Francisco, noted that discontinuing medication is common for people being treated for obesity and other conditions. Kim was likewise not involved in the new study. Kim added that adherence to medication schedules as well as diet and exercise programs isn't as easy in real life because people don't have the supervision and support a person gets during a clinical trial. 'Real life is different and results aren't always as spectacular as in clinical trials,' Kim told Healthline. Kim and Ali agreed that another reason people stop taking medications is that these drugs can be expensive, even if insurance is picking up part of the cost. There is also the fact that the side effects from these medications can be severe for some people. Plus, people in real life sometimes just get tired of the obligation of taking a pill or injecting themselves on a regular basis. Ali and Kim also noted that people need to realize that medications are only a tool to help them eat less. To lose weight and keep it off, a person needs to adopt lifestyle habits such as a healthy diet and regular exercise. 'The medications are not a short-term kickstart. They don't burn fat,' said Kim. 'The medications just help with the suppression of hunger.' 'The ultimate goal of the medications is to give people a tool to get them to a healthy weight,' Ali added. What to know about GLP-1 drug for weight loss Glucagon-like peptide-1 receptor agonists (GLP-1s) work by mimicking a hormone in the body that helps regulate blood sugar levels and reduces hunger pangs. One class of the newer GLP-1 medications uses the active ingredient semaglutide. They are sold under different brand names. Ozempic and Rybelsus have been approved to treat type 2 diabetes. Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections. The other newer group uses the active ingredient tirzepatide. Mounjaro is approved to treat type 2 diabetes. Zepbound is approved for use in weight management. These medications are available only as injections. Previous studies have highlighted the effectiveness of these drugs on helping people lose weight. Past research has also indicated that these weight loss drugs can help lower a person's risk of cancer as well as provide benefits to heart health and brain health. Experts say the medications have proven to be effective and their use is likely to increase. 'This is a massive market and it's not going to go away,' Ali said. 'These medications are going to continue to be a big part of weight loss programs.'

Yahoo

2 hours ago

• Yahoo

The summer solstice is today. Here's what to expect on the 1st day of summer.

Today will be the longest day of 2025 in the Northern Hemisphere, kicking off the coveted summer season. The 2025 summer solstice is expected to officially start on June 20 at 10:42 p.m. ET, according to the Farmers Almanac. It's at that time that the sun will be at its northernmost point for the Northern Hemisphere. Astronomers recognize the summer solstice as the first day of summer, although it's not necessarily considered the 'official' start of summer. 'The June solstice marks a precise moment in Earth's orbit — a consistent astronomical signpost that humans have observed for millennia,' NASA says. 'Ancient structures from Stonehenge to Chichén Itzá were built, in part, to align with the solstices, demonstrating how important these celestial events were to many cultures.' Thousands of visitors are expected to flock to areas throughout the Northern Hemisphere to celebrate through rituals: from Stonehenge in Wiltshire, England, to midsummer festivals across Sweden, Denmark, Norway and Finland. Here's what to know about the summer solstice. 'Solstice' comes from the Latin words 'sol' (meaning sun) and 'sistere' (to stand still), according to the Farmers' Almanac, and it describes the Earth's angle between the sun's rays. The summer solstice is the longest day of the year for the Northern Hemisphere because this is when the Earth's north pole is tilted toward the sun at its most extreme angle. Solstices only happen twice a year, the second time being when the Northern Hemisphere experiences its winter solstice in December, which is when the Earth's south pole is tilted toward the sun at its most extreme angle. On Friday, the Northern Hemisphere will experience its official first days of summer and longest hours of daylight for the entire year. Areas around the equator will experience sunlight for about 12 hours straight, according to while more mid-northern areas will get 15 hours. Since the Earth's north pole is tilted so close to the sun, areas north of the Arctic Circle will experience sunlight for 24 hours. The summer solstice can happen anytime between June 20 and June 22, depending on the time zone. While we measure years in 365 days — or 366 days for a leap year — astronomically speaking, Earth actually takes 365.242199 days to orbit the sun. This affects what time and day the summer solstice will actually occur. In a lot of Northern Hemisphere locations, areas will experience earlier sunrises before the official solstice day, and some later sunsets happen days after it, according to Time and Date, a global platform that analyzes time zone and astronomy data. The solstice day never being official or aligned every year is common since the sun's solar time is never precise or consistent with how our clocks and calendars operate. Astronomers have studied the sun's timing compared to how we measure time with clocks and calendars, and refer to the difference as 'the equation of time.' Solstices and equinoxes seem to kick off a change in the seasons on Earth, but there are significant differences between the two experiences. Just compare the 2025 spring equinox, which happened on March 20, to what is expected to happen during the upcoming summer solstice on Friday. Summer and winter solstices are when the Earth's tilt toward the sun is at its maximum, so the summer solstice is when the Northern Hemisphere experiences its longest day of sunlight and shortest night, and the winter solstice is when the Northern Hemisphere experiences its shortest day of sunlight and longest night. During an equinox, the Earth is not tilted anywhere directly, and the sun falls right over the equator, which means that there will be 'nearly' equal amounts of daylight and darkness at all latitudes, according to the National Weather Service.

Medscape

3 hours ago

• Medscape

Nurse Practitioners Fill Gaps as Geriatricians Decline

On Fridays, Stephanie Johnson has a busy schedule, driving her navy-blue Jeep from one patient's home to the next, seeing eight in all. Pregnant with her second child, she schleps a backpack instead of a traditional black bag to carry a laptop and essential medical supplies — stethoscope, blood pressure cuff, and pulse oximeter. Forget a lunch break; she often eats a sandwich or some nuts as she heads to her next patient visit. On a gloomy Friday in January, Johnson, a nurse practitioner who treats older adults, had a hospice consult with Ellen, a patient in her 90s in declining health. To protect Ellen's identity, KFF Health News is not using her last name. 'Hello. How are you feeling?' Johnson asked as she entered Ellen's bedroom and inquired about her pain. The blinds were drawn. Ellen was in a wheelchair, wearing a white sweater, gray sweatpants, and fuzzy socks. A headband was tied around her white hair. As usual, the TV was playing loudly in the background. 'It's fine, except this cough I've had since junior high,' Ellen said. Ellen had been diagnosed with vascular dementia, peripheral vascular disease, and type 2 diabetes. Last fall, doctors made the difficult decision to operate on her foot. Before the surgery, Ellen was always colorful, wearing purple, yellow, blue, pink, and chunky necklaces. She enjoyed talking with the half dozen other residents at her adult family home in Washington state. She had a hearty appetite that brought her to the breakfast table early. But lately, her enthusiasm for meals and socializing had waned. Johnson got down to eye level with Ellen to examine her, assessing her joints and range of motion, checking her blood pressure, and listening to her heart and lungs. Carefully, Johnson removed the bandage to examine Ellen's toes. Her lower legs were red but cold to the touch, which indicated her condition wasn't improving. Ellen's two younger sisters had power of attorney for her and made it clear that, above all, they wanted her to be comfortable. Now, Johnson thought it was time to have that difficult conversation with them about Ellen's prognosis, recommending her for hospice. 'Our patient isn't just the older adult,' Johnson said. 'It's also often the family member or the person helping to manage them.' Nurse practitioners are having those conversations more and more as their patient base trends older. They are increasingly filling a gap that is expected to widen as the senior population explodes and the number of geriatricians declines. The Health Resources and Services Administration projects a 50% increase in demand for geriatricians from 2018 to 2030, when the entire baby boom generation will be older than 65. By then, hundreds of geriatricians are expected to retire or leave the specialty, reducing their number to fewer than 7600, with relatively few young doctors joining the field. That means many older adults will be relying on other primary care physicians, who already can't keep up with demand, and nurse practitioners, whose ranks are booming. The number of nurse practitioners specializing in geriatrics has more than tripled since 2010, increasing the availability of care to the current population of seniors, a recent study in JAMA Network Open found. According to a 2024 survey, of the roughly 431,000 licensed nurse practitioners, 15% are, like Johnson, certified to treat older adults. Johnson and her husband, Dustin, operate an NP-led private practice in greater Seattle, Washington, a state where she can practice independently. She and her team, which includes five additional nurse practitioners, each try to see about 10 patients a day, visiting each one every 5-6 weeks. Visits typically last 30 minutes to an hour, depending on the case. 'There are so many housebound older adults, and we're barely reaching them,' Johnson said. 'For those still in their private homes, there's such a huge need.' Laura Wagner, a professor of nursing and community health systems at the University of California, San Francisco, stressed that nurse practitioners are not trying to replace doctors; they're trying to meet patients' needs, wherever they may be. 'One of the things I'm most proud of is the role of nurse practitioners,' she said. 'We step into places where other providers may not, and geriatrics is a prime example of that.' Practice Limits Nurse practitioners are registered nurses with advanced training that enables them to diagnose diseases, analyze diagnostic tests, and prescribe medicine. Their growth has bolstered primary care, and, like doctors, they can specialize in particular branches of medicine. Johnson, for example, has advanced training in gerontology. 'If we have a geriatrician shortage, then hiring more nurse practitioners trained in geriatrics is an ideal solution,' Wagner said, 'but there are a lot of barriers in place.' In 27 states and Washington, DC, nurse practitioners can practice independently. But in the rest of the country, they need to have a collaborative agreement with or be under the supervision of another health care provider to provide care to older adults. Medicare generally reimburses for nurse practitioner services at 85% of the amount it pays physicians. Last year, in more than 40 states, the American Medical Association and its partners lobbied against what they see as 'scope creep' in the expanded roles of nurse practitioners and other health workers. The AMA points out that doctors must have more schooling and significantly more clinical experience than nurse practitioners. While the AMA says physician-led teams keep costs lower, a study published in 2020 in Health Services Research found similar patient outcomes and lower costs for nurse practitioner patients. Other studies, including one published in 2023 in the journal Medical Care Research and Review , have found healthcare models including nurse practitioners had better outcomes for patients with multiple chronic conditions than teams without an NP. Five states have granted NPs full practice authority since 2021, with Utah the most recent state to remove physician supervision requirements, in 2023. In March, however, Mississippi House Bill 849, which would have increased NP independence, failed. Meanwhile, 30 Texas physicians rallied to tamp down full-scope efforts in Austin. 'I would fully disagree that we're invading their scope of practice and shouldn't have full scope of our own,' Johnson said. She has worked under the supervision of physicians in Pennsylvania and Washington state but started seeing patients at her own practice in 2021. Like many nurse practitioners, she sees her patients in their homes. The first thing she does when she gets a new patient is manage their prescriptions, getting rid of unnecessary medications, especially those with harsh side effects. She works with the patient and a family member who often has power of attorney. She keeps them informed of subtle changes, such as whether a person was verbal and eating and whether their medical conditions have changed. While there is some overlap in expertise between geriatricians and nurse practitioners, there are areas where nurses typically excel, said Elizabeth White, an assistant professor of health services, policy, and practice at Brown University. 'We tend to be a little stronger in care coordination, family and patient education, and integrating care and social and medical needs. That's very much in the nursing domain,' she said. That care coordination will become even more critical as the US ages. Today, about 18% of the US population is 65 or over. In the next 30 years, the share of seniors is expected to reach 23%, as medical and technological advances enable people to live longer. Patient and Family In an office next to Ellen's bedroom, Johnson called Ellen's younger sister Margaret Watt to recommend that Ellen enter hospice care. Johnson told her that Ellen had developed pneumonia and her body wasn't coping. Watt appreciated that Johnson had kept the family apprised of Ellen's condition for several years, saying she was a good communicator. 'She was accurate,' Watt said. 'What she said would happen, happened.' A month after the consult, Ellen died peacefully in her sleep. 'I do feel sadness,' Johnson said, 'but there's also a sense of relief that I've been with her through her suffering to try to alleviate it, and I've helped her meet her and her family's priorities in that time.'